QMS Medical Allied Services Ltd began three decades ago as a one-man pharma marketing outfit and has since transformed into a technology-enabled healthcare platform that sits between India’s drug makers, doctors, and patients. The business was built by spotting what the pharmaceutical industry needed next - first, reliable distribution of diagnostic devices, then structured camps to screen patients at clinics, and now end-to-end programs that keep patients on their treatment plans long after the prescription is written. The recurring approach is to own the relationship and the data layer while leaving manufacturing to others, stitching together global device brands, an in-house software backbone, and a network of paramedics and dieticians into a single service that pharma companies pay for. # Business segments Two engines that feed each other - a medical-products distribution business that built the client relationships and a higher-margin healthcare-services business that deepens them, both running on the same in-house technology platform. ## 1. Medical products distribution: the relationship engine that puts devices into clinics and homes **QMS sources, brands, and sells diagnostic devices and consumables through three distinct channels - direct sales to pharma companies, its own e-commerce site, and a government-backed rural network - without owning a single factory.** - **Exclusive brand gatekeeper** - the company holds long-standing exclusive distribution rights for global device makers like 3M (since 1994), Heine (since 2008), and Bio-Sense Diagnostics (since 2018), which means pharma companies and hospitals come to QMS for products they cannot source elsewhere. - **Own brand for better margins** - in 2023 it launched “Q Devices,” its in-house label of wellness and medical devices such as knee braces, nebulizers, and blood pressure monitors, giving it control over quality and supply chain while earning higher margins than third-party distribution. - **Three routes to the customer** - it sells B2B to over 130 institutional clients including more than 50 pharma companies; B2C through its own comparison-shopping platform QMSMEDS and marketplaces like Amazon and Blinkit; and into rural India as the first healthcare vendor on the government’s eGrameen portal, tapping 5.5 lakh-plus Village Level Entrepreneurs for last-mile delivery. - **Moving into hospital shelves** - since FY25 it has added hospital supply tie-ups in cities like Indore and Ahmedabad, and in mid-2024 signed distributor agreements for specialized cardiac stents and aortic balloon valves, expanding beyond clinic-focused devices into procedure-ready consumables. - **Licence as a barrier** - the company holds a CDSCO licence, a regulatory requirement that creates a high entry barrier for would-be competitors who lack the compliance infrastructure. ## 2. Healthcare services: the higher-margin engine that runs screening camps and patient support programs for pharma companies **QMS designs and operates the field infrastructure - paramedics, dieticians, diagnostic kits, and a digital app - that lets pharmaceutical companies screen patients at doctor clinics and then keep those patients on therapy, earning service fees that carry roughly double the margin of product sales.** - **Camps as a service** - pharma companies use their medical representatives to bring doctors and patients together, while QMS supplies the 135 trained DMLT-certified paramedics, USFDA-approved diagnostic devices, and logistics to run the camp, conducting over 32,000 such camps in FY26 alone. - **Patient support programs that begin after the prescription** - once a doctor prescribes treatment, QMS takes over the patient journey with counseling, reminders, lifestyle coaching, and outcome monitoring, all aimed at keeping patients compliant with chronic-disease treatment plans across therapy areas from cardiology to ophthalmology. - **The Saarathi bolt-on** - the acquisition of a 76% stake in Saarathi Healthcare, a pioneer with over 16 years in disease management, brought 1,000-plus completed projects and expertise in oncology, rare diseases, and chronic kidney care, letting QMS cover the full patient journey from diagnosis through long-term therapy adherence. - **A clean-slate spending opportunity** - India’s pharma market is roughly Rs 2 lakh crores with around Rs 12,000 crores in promotional spend, yet almost none of it is earmarked for structured patient services, giving QMS a wide-open field as regulators push for more patient engagement over direct promotion. # Technology platform **A single in-house digital backbone connects every product sold and every patient served, giving pharma clients real-time visibility and giving QMS a reason to be more than a middleman.** - **Built, not bought** - the cloud-based, AWS-hosted application was developed entirely by QMS’s own software team, ensuring it fits the company’s camp and patient-support workflows rather than forcing those workflows into a generic tool. - **Over a million patients tracked** - the platform serves more than 1 million patients, supports over 100 programs, and engages 350,000-plus healthcare professionals, with a centralized CRM that lets pharma clients see real-time analytics on patient engagement and adherence. - **AI spotting at-risk patients** - the system uses artificial intelligence to monitor patient data and flag those at risk of dropping off treatment, enabling personalized interventions before a patient disengages. # Group structure and partners **QMS is a promoter-led company with a recently upgraded main-board listing, a majority-owned patient-support subsidiary, and distribution agreements that reach from global device giants to India’s rural e-governance network.** - **Promoter control and main-board migration** - founder and managing director Mahesh Makhija held roughly 72% of the company as of FY24, and the stock migrated from the NSE Emerge platform to the NSE Main Board in June 2026. - **Saarathi Healthcare subsidiary** - QMS owns 76% of Saarathi, acquired in two tranches during 2024-25 and funded partly by a Rs 12.5 crore rights issue, consolidating it as a subsidiary with a minority interest of Rs 18.1 crore as of September 2025. - **Global device partnerships** - exclusive channel relationships with 3M (since 1994), Heine (since 2008), and Bio-Sense Diagnostics (since 2018), plus a distribution partnership with Omron Healthcare in India, supply the product portfolio QMS sells across all its channels. - **Government rural reach** - an agreement with CSC e-Governance Services India and approved-vendor status on the eGrameen portal give QMS access to over 5.5 lakh Village Level Entrepreneurs for delivering healthcare products to rural households. - **Smaller acquisitions and promoter entities** - QMS is in the process of acquiring 100% of Prometheus Healthcare, a digital-marketing and conference-services firm, while the promoter’s other directorships (ABAE Technologies, Queen’s Promotional Services, UMC Medical) sit outside the listed company’s business lines.